Capsule Summary Slidesets

Share

Program Content

Activities

  • FIGHT-203: Pemigatinib in MLN<sup><i>FGR1</i></sup>
    FIGHT-203: Phase II Trial of Pemigatinib in Patients With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2021

    Expires: December 13, 2022

  • CPX-351 in HR MDS
    Phase II Trial of CPX-351 as First-line Treatment in Patients With Higher-Risk MDS
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2021

    Expires: December 13, 2022

  • Sabatolimab + HMA in MDS/AML
    Phase Ib Study of Sabatolimab + Hypomethylating Agents for Very High–Risk/High-Risk MDS and Newly Diagnosed AML: Final Analysis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2021

    Expires: December 13, 2022

  • Venetoclax/Azacitidine in MDS
    Phase Ib Study: Venetoclax/Azacitidine in Treatment-Naive Higher-Risk MDS
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2021

    Expires: December 14, 2022

  • IPSS-M Development
    Development and Validation of a Molecular International Prognostic Scoring System (IPSS-M) for MDS Risk Stratification
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2021

    Expires: December 14, 2022

  • Pelabresib in MF
    MANIFEST: Pelabresib (CPI-0610) Monotherapy in Patients With Myelofibrosis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2021

    Expires: December 15, 2022

  • Rusfertide in PV
    Phase II Trial of Rusfertide (PTG-300) in Patients With Phlebotomy-Dependent Polycythemia Vera
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2021

    Expires: December 15, 2022

  • HMA + Ven in MDS
    Retrospective Analysis of Venetoclax + Hypomethylating Agents for Patients With Higher-Risk Myelodysplastic Syndromes
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2021

    Expires: December 16, 2022

  • CPX-351 in Higher-Risk MDS
    Pilot Study of CPX-351 in Transplant-Eligible Patients With Previously Untreated Higher-Risk MDS
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2021

    Expires: December 16, 2022

  • PANTHER
    PANTHER: Randomized Phase III Trial of First-line Pevonedistat + Azacitidine vs Azacitidine in Higher-Risk MDS/CMML or AML With 20% to 30% Marrow Blasts
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 20, 2021

    Expires: December 19, 2022

  • MDS: LEN ± ELT
    Phase II Trial of Lenalidomide and Eltrombopag for Low-Risk/Intermediate-Risk MDS
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation